DO DOCS Doximity, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Doximity uses Fireworks for clinical AI that lets doctors ask deep medical questions, match symptoms to medications and side effects, and research medical topics. It topped the Stanford/Harvard clinical safety benchmark, showing how domain-specific healthcare data and post-training can produce superior clinical AI.

Shkreli asks a rhetorical clarifying question about the DOCS trade without stating his own position or direction.

Author notes earnings gaps in AKAM, NET, and DOCS as software group looks good but lacks follow-through, a factual observation without explicit positions.

Doximity (DOCS) spiked on AI hype but fundamentals are weakening with negative revenue and EPS acceleration. He exited the position and would not buy back given the poor momentum.

US pre-market movers show strong gains for NET, ABNB, MCHP, TEAM, CART, MP, and DV on earnings or acquisition news, while RMD, TTD, and SG decline on misses or guidance cuts.

Short DOCS as a forced-seller catalyst (a pod shop blowing up) creates technical selling pressure, while the underlying quarter was uninspiring — offering a clean entry on the short side.

Premarket movers show mixed megacap tech, with strong earnings-driven gains in AAOI, TEAM, NET, DOCS, FIGS, and CART, while DKNG, SEZL, SG, and TTD fall on disappointing results or outlooks.

The tweet cryptically labels DOCS as "MEDP 2.0," implying a bearish comparison to Medpace's trajectory, but lacks explicit short positioning or a reasoned downside call.

Doximity reports Q1 revenue of 156.6 million dollars, up 7 percent year-over-year, with non-GAAP EPS of 0.29 dollars and record engagement driven by AI assistant growth.

Comcast plans to spin off NBCUniversal and Sky assets, while Charter and SPCX discuss a mobile partnership and Palantir delivers an AI platform with Nvidia.

Premarket movers include Magnificent Seven stocks all higher, Comcast up 22% on spin-off plans, Doximity down 4% on BofA downgrade, Iridium up 20% on Rocket Lab acquisition, Martin Marietta down 3% on deal, and Viridian up 14% on FDA approval.

Doximity shares fell 23.3% to a record low after a cautious FY26 revenue outlook trailing consensus, with rising AI costs compressing margins and a Quant Rating of Hold.

Bearish view on these names as structurally declining assets akin to linear TV; cheapness is a value trap with persistent selling pressure and zero terminal value.

Bearish view on $DOCS as competitor EvidenceOpen is disrupting the industry within two years of launch, rapidly gaining market share.

Author argues Doximity is a high-quality, 80%-penetrated U.S. physician network trading below intrinsic value because 16 of its top 20 pharma clients delayed ad budgets amid Most Favored Nation drug-pricing uncertainty. The claimed mechanism is that the budget freeze is temporary, leaving 89.75% gross margins, 23.59% ROIC, $724M net cash, 112%/117% NRR, and a $500M buyback intact while January 2026 bookings hit records. Valuation uses 20x owner earnings plus net cash to reach $28.44 intrinsic value versus $24.00 current price, a 15.6% margin of safety, with management expecting a return to double-digit growth as budgets thaw. Main author-stated risks are market saturation/user-growth ceiling, revenue-per-user slowdown, permanent pharma budget shifts, and lumpy pharma spending.

The author argues Doximity's 80%+ US physician network, ~90% gross margins, 23% YoY revenue growth and profitable free cash flow are being mispriced after an AI-prompted selloff. The causal mechanism is that healthcare compliance, trust and distribution protect its pharma advertising and workflow revenue, while DoxGPT becomes an AI tailwind. The concrete catalyst is one good quarter or a major pharma partnership, potentially repricing the stock back to $65-80+, with the main stated risk being AI competition from OpenAI/Google/startups cracking healthcare compliance.

The author argues Doximity is a high-quality, profitable healthcare platform trading below intrinsic value. He cites strong profitability (net income, high margins), net cash, accelerating AI adoption, and recent estimate beats as drivers. The main upside catalyst is continued growth and analyst price targets around $68 (~47% upside); the main stated risks are pharma marketing budget uncertainty for 2026 and political hostility to direct-to-consumer drug marketing.